γ-Mangostin Ameliorates Free Fatty Acid-Induced Lipid Accumulation via the SIRT1/LKB1/AMPK Pathway in HepG2 and L02 Cells

被引:30
作者
Gu, Liang [1 ]
Cai, Nan [1 ,2 ]
Lyu, Yansi [3 ]
Yao, Lijun [1 ]
Wang, Fei [4 ]
Xu, Hong [1 ]
Hu, Zhangli [1 ]
Li, Hui [1 ]
Xu, Xu [1 ]
机构
[1] Shenzhen Univ, Shenzhen Key Lab Marine Bioresource & Ecoenvironm, Guangdong Prov Key Lab Plant Epigenet,Coll Life S, Coll Optoelect Engn,Minist Educ & Guangdong Prov, Shenzhen 518060, Guangdong, Peoples R China
[2] Shenzhen Univ, Key Lab Optoelect Devices & Syst, Minist Educ & Guangdong Prov, Coll Optoelect Engn, Shenzhen 518060, Guangdong, Peoples R China
[3] Shenzhen Univ, Gen Hosp, Dept Dermatol, Shenzhen 518055, Guangdong, Peoples R China
[4] Shenzhen Univ, Gen Hosp, Dept Spine Surg, Shenzhen 518055, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
the AMPK pathway; Compound C; alpha-mangostin; gamma-mangostin; nonalcoholic fatty liver disease (NAFLD); ACTIVATED PROTEIN-KINASE; LIVER-DISEASE; GARCINIA-MANGOSTANA; ALPHA-MANGOSTIN; METABOLISM; STEATOSIS; ENERGY; ROLES; LKB1;
D O I
10.1021/acs.jafc.9b05632
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Lipid accumulation is a typical characteristic of nonalcoholic fatty liver disease (NAFLD). The inhibition of lipid accumulation is regarded as a potential treatment for NAFLD. In this study, we investigated the effects of gamma-mangostin or alpha-mangostin on lipid accumulation in a cell model. Analysis of the inhibitory effects of gamma-mangostin on lipid accumulation revealed that it downregulated NAFLD-related biochemical parameters and stimulated the SIRT1/LKB1/AMPK pathway. Consequently, it suppressed lipid synthesis and enhanced fatty acid oxidation. Moreover, we demonstrated that the blockage of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C abrogated the promoting effect of AMPK. Similar results were also observed for alpha-mangostin. The effects of alpha-mangostin on lipid accumulation were inferior to those of gamma-mangostin. The differences in CPT1A activity might be originated from their different chemical structures. Our results suggested that gamma-mangostin and alpha-mangostin can be exploited as potential candidates for NAFLD treatment.
引用
收藏
页码:13929 / 13938
页数:10
相关论文
共 33 条
[1]   The Sir2 family of protein deacetylases [J].
Blander, G ;
Guarente, L .
ANNUAL REVIEW OF BIOCHEMISTRY, 2004, 73 :417-435
[2]   Potential effects of α-mangostin in the prevention and treatment of hepatocellular carcinoma [J].
Cai, Nan ;
Xie, Shu-Juan ;
Qiu, Dong-Bo ;
Jia, Chang-Chang ;
Du, Cong ;
Liu, Wei ;
Chen, Jia-Jie ;
Zhang, Qi .
JOURNAL OF FUNCTIONAL FOODS, 2016, 26 :309-318
[3]   Mangosteen Extract Attenuates the Metabolic Disorders of High-Fat-Fed Mice by Activating AMPK [J].
Chae, Hee-Sung ;
Kim, Young-Mi ;
Bae, Jin-Kyung ;
Sorchhann, Sochivak ;
Yim, Sreymom ;
Han, Ling ;
Paik, Jin Hyub ;
Choi, Young Hee ;
Chin, Young-Won .
JOURNAL OF MEDICINAL FOOD, 2016, 19 (02) :148-154
[4]   Bioactivity and pharmacological properties of α-mangostin from the mangosteen fruit: a review [J].
Chen, Guoqing ;
Li, Yong ;
Wang, Wei ;
Deng, Liping .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (05) :415-427
[5]  
Chen K, 2019, FOOD FUNCT, V10, P814, DOI [10.1039/c8fo01236a, 10.1039/C8FO01236A]
[6]   Anti-inflammatory activity of mangostins from Garcinia mangostana [J].
Chen, Lih-Geeng ;
Yang, Ling-Ling ;
Wang, Ching-Chiung .
FOOD AND CHEMICAL TOXICOLOGY, 2008, 46 (02) :688-693
[7]   Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement [J].
Chin, Young-Won ;
Kinghorn, A. Douglas .
MINI-REVIEWS IN ORGANIC CHEMISTRY, 2008, 5 (04) :355-364
[8]   α-Mangostin Regulates Hepatic Steatosis and Obesity through SirT1-AMPK and PPARγ Pathways in High-Fat Diet-Induced Obese Mice [J].
Choi, Young Hee ;
Bae, Jin Kyung ;
Chae, Hee-Sung ;
Kim, Young-Mi ;
Sreymom, Yim ;
Han, Ling ;
Jang, Ha Young ;
Chin, Young-Won .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2015, 63 (38) :8399-8406
[9]  
Collins R, 2003, LANCET, V361, P2005
[10]   Nonalcoholic fatty liver disease: From steatosis to cirrhosis [J].
Farrell, GC ;
Larter, CZ .
HEPATOLOGY, 2006, 43 (02) :S99-S112